Edwards Lifesciences (EW) Stock Looks Fully Priced On Cash Flow

Edwards Lifesciences has delivered a strong share gain in recent years, and a fresh swing in sentiment after new clinical data now puts the spotlight squarely on one question for investors: Are today’s cash flows and their future path enough to support the current stock price?

• Over the past 3 years, Edwards Lifesciences has returned about 50.0%, which makes the link between that share price climb and the durability of its cash generation especially important to scrutinize.
• Results from the PROGRESS trial showed clinical benefits for transcatheter aortic valve replacement in moderate aortic stenosis, which can shape expectations for how quickly Edwards Lifesciences might convert more of its pipeline into cash flows and how much investment it may need to support that opportunity.
• If you'd rather focus on earnings, this one's for you. See what Edwards Lifesciences's 58.5x P/E says about the price.

The issue now is whether the stock’s recent price around US$99 reflects an intrinsic value that can be supported by Edwards Lifesciences' cash flows under a Discounted Cash Flow (DCF) view.

If you want more than one case study on how cash flows stack up against price, a focused stock screen built around 35 high quality undervalued stocks can be a useful next step in your research.

Has Edwards Lifesciences Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on the cash Edwards Lifesciences can return to shareholders over time. Latest twelve month free cash flow sits at about $1.40b, and the model assumes those cash flows continue growing rather than shrinking, with forecasts stepping up into the late 2020s before easing into a slower pace.

On that set of cash flow estimates, the DCF points to an intrinsic value that is meaningfully below the current share price of $99.37. Because the PROGRESS trial raised questions about how much the TAVR market might actually widen, it helps explain why a cash flow based model can sit below where the stock trades today. For readers who want to see the detailed assumptions behind that gap, the full valuation model is here. Find out what Edwards Lifesciences could be worth using our Discounted Cash Flow (DCF) estimate.

The Edwards Lifesciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Edwards Lifesciences valuation gap above leaves off. On the Community page, they spell out which assumptions on growth, margins and earnings would need to hold for the share price to sit meaningfully higher or lower than it does today. Each narrative turns that implied fair value into a clear, testable idea about Edwards Lifesciences' business so you can see how the reasoning holds up over time.

One of the top community narratives on Edwards Lifesciences: roughly fairly valued

"The main factor that has to go right is successful execution on the multi-platform structural heart strategy…"

Discover why this Narrative puts Edwards Lifesciences at roughly fairly valued.

One more Edwards Lifesciences question that could change your view

Edwards Lifesciences is more than its cash flow profile, because internal checks have also flagged specific business risks that could shift how you think about the stock once you see them. Take a closer look at 2 warning signs before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com